Among the new products, Bausch + Lomb's Lumify redness reliever eye drops are providing innovation and growth to the eye care category as the first and only O-T-C drops containing low-dose brimonidine tartrate
. Backed by six clinical studies, Lumify has a strong efficacy and safety profile with low risk for rebound redness and 95% symptom improvement seen at one minute and lasting up to eight hours.
Bausch + Lomb announced the launch of LUMIFY, the first and only over-the-counter eye drop developed with low-dose brimonidine tartrate
for the treatment of eye redness.
For persistent erythema, topical alpha-adrenergic receptor agonists including brimonidine tartrate
and oxymetazoline have been shown to reduce erythema by vasoconstricting blood vessels, although some products are associated with a rebound erythema on treatment discontinuation.
IOP of the OD remained consistently above 50 mmHg with medications provided (i.e., travoprost, timolol, brinzolamide, brimonidine tartrate
, and mannitol 20%).
Can be pro-inflammatory in CMO, reactivate herpes simplex Apraclonidine lopidine Sympathomimetics 0.5% 5mL BC alpha2 Aqonists 1.0% unlicensed for Preservative free Stinging/burning, glaucoma allergy, blurring Brimonidine tartrate Brimonidine Tartrate
Conjunctival 0.2% 5mL BC erythema, dry mouth, 0.2% 5mL Alphagan headache, drowsiness, Neuro-protective BC fatigue, dizziness, in NTG gastro intestinal symptoms Acetazolamide Diamox Carbonic anhydrase 250mg tablet inhibitors 500mg powder for Diamox SR Electrolyte injection 250mg Sustained release disturbances.
M2 PHARMA-August 10, 2017-FDA Grants Ocugen Orphan Drug Designation for OCU300 (brimonidine tartrate
) for Treatment of Ocular Graft Versus Host Disease
These drugs with neuroprotective properties are being investigated as treatments for dry AMD: an implanted encapsulated cell technology (NT-501, Neurotech); intravitreal brimonidine tartrate
(Allergan); and topical tandospirone (AL-8309B; Alcon) [Table 2].
The effect of brimonidine tartrate
on retinal blood flow in patients with ocular hypertension.
Hasanreisoglu, "Neuroprotective effect of topically applied brimonidine tartrate
0.2% in endothelin-1-induced optic nerve ischaemia model," Clinical and Experimental Ophthalmology, vol.
A 1-year, open-label safety trial evaluated approximately 345 subject-years of exposure to brimonidine tartrate
is a potent third generation alpha-2 adrenergic agonist and has more than 1000-fold selectivity for alpha-2 over alpha-1 receptors.
The two coming attractions are brimonidine tartrate
0.5% gel and oxymetazoline cream.